A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

Journal of Proteomics

Volumn 116, Issue , 2015, Pages 59-67

  Hare, Brian J ^a   Haseltine, Eric ^a   Fleming, Mark ^a   Chelsky, Daniel ^b   McIntosh, Laura ^b   Allard, Rene ^b   Botfield, Martyn ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b Caprion Proteomics   (Canada)

Author keywords

Direct acting antiviral; Focal adhesion; Proteomic profiling; Response predictor; Telaprevir

Indexed keywords

APOLIPOPROTEIN A4; AZGP1 PROTEIN; C9 PROTEIN; CLIC1 PROTEIN; CNDP1 PROTEIN; FERMT3 PROTEIN; GLUTATHIONE TRANSFERASE P1; INTEGRIN; LGALS3BP PROTEIN; ORM1 PROTEIN; PARVA PROTEIN; PEGINTERFERON; PEPTIDES AND PROTEINS; PFN1 PROTEIN; PROTEIN; RIBAVIRIN; TAGLN2 PROTEIN; TELAPREVIR; TLN1 PROTEIN; UNCLASSIFIED DRUG; VCL PROTEIN; ZYX PROTEIN; ANTIVIRUS AGENT;

ACTIN FILAMENT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; FOCAL ADHESION; HEPATITIS C; HUMAN; IMMUNE RESPONSE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; MALE; METABOLISM; MORTALITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

HEPATITIS C VIRUS;

ACTIN CYTOSKELETON; ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOCAL ADHESIONS; HEPATITIS C; HUMANS; INTEGRINS; MALE;

EID: 84921491326     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.12.015     Document Type: Article

References (44)

1. World Health Organization Hepatitis C: surveillance and control 2012 http://www.who.int/csr/disease/hepatitis/GHP_framework.pdf.
2. Davis G. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338. 10.1053/jlts.2003.50073.
3. El-Serag H.B. Hepatocellular carcinoma. N Engl J Med 2011, 365:1118-1127. 10.1056/NEJMra1001683.
4. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomised trial of interferon alpha2b plus ribavirin for 48weeks or for 24weeks versus interferon alpha2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus 1998, 352.
5. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
6. Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006, 52:1887-1896. 10.1373/clinchem.2006.070961.
7. Guidelines C.P. EASL Clinical Practice Guidelines: management of hepatitis C virus infection 2011, 55.
8. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401. 10.1038/nature08309.
9. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. [e18]. 10.1053/j.gastro.2010.04.013.
10. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H.T., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008, 105:7034-7039. 10.1073/pnas.0707882105.
11. Patel K., Lucas J.E., Thompson J.W., Dubois L.G., Tillmann H.L., Thompson A.J., et al. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology 2011, 53:1809-1818. 10.1002/hep.24284.
12. Lin C., Kwong a D., Perni R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006, 6:3-16.
13. SOVALDI [US Prescribing Information] http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
14. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.a, Jacobson I.M., Afdhal N.H., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303. 10.1056/NEJMoa0908014.
15. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV Genotype 1 infection. N Engl J Med 2011, 364:1195-1206. 10.1056/NEJMoa1010494.
16. Lange C.M., Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013, 58:583-592. 10.1016/j.jhep.2012.10.019.
17. Poordad F., Lawitz E., Kowdley K.V., Everson G.T., Freilich B., Cohen D. 12-Week interferon-free regimen of ABT-450/R+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and in 47% of previous non-responders. J Hepatol 2012, 56:549-550.
18. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850. 10.1056/NEJMoa0807650.
19. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838. 10.1056/NEJMoa0806104.
20. Beretta L. The human liver proteome project. Mol Cell Proteomics 2007, 6:2043.
21. Royston P., Altman D.G., Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25:127-141. 10.1002/sim.2331.
22. Liu J., Florian J., Birnkrant D., Murray J., Jadhav P.R. Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions. Clin Infect Dis 2012, 55:639-644. 10.1093/cid/cis510.
23. Gangadharan B., Bapat M., Rossa J., Antrobus R., Chittenden D., Kampa B., et al. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 2012, 7:e39603. 10.1371/journal.pone.0039603.
24. Artini M., Natoli C., Tinari N., Costanzo A., Marinelli R., Balsano C., et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996, 25:212-217.
25. Dill M.T., Duong F.H.T., Vogt J.E., Bibert S., Bochud P.-Y., Terracciano L., et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140:1021-1031. 10.1053/j.gastro.2010.11.039.
26. Blomme B., Van Steenkiste C., Callewaert N., Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol 2009, 50:592-603. 10.1016/j.jhep.2008.12.010.
27. Mosnier J.-F., Scoazec J.-Y., Marcellin P., Degott C., Benhamou J.-P., Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 1994, 107:1457-1468. 1016/0016-5085(94)90550-9.
28. Wehrle-Haller B. Structure and function of focal adhesions. Curr Opin Cell Biol 2012, 24:116-124. 10.1016/j.ceb.2011.11.001.
29. Feng C., Li Y.-F., Yau Y.-H., Lee H.-S., Tang X.-Y., Xue Z.-H., et al. Kindlin-3 mediates integrin αLβ2 outside-in signaling, and it interacts with scaffold protein receptor for activated-C kinase 1 (RACK1). J Biol Chem 2012, 287:10714-10726. 10.1074/jbc.M111.299594.
30. A heterozygous mutation of beta-actin associated with neutrophil dysfunction and recurrent infection. Proc Natl Acad Sci U S A 1999, 96:8693-8698.
31. Leung W.K.C., Ching a K.K., Chan a W.H., Poon T.C.W., Mian H., Wong a S.T., et al. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 2011, 30:4464-4475.
32. Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med 2012, 52:1135-1150. 10.1016/j.freeradbiomed.2012.01.008.
33. De Chassey B., Navratil V., Tafforeau L., Hiet M.S., Aublin-Gex a, Agaugué S., et al. Hepatitis C virus infection protein network. Mol Syst Biol 2008, 4:230. 10.1038/msb.2008.66.
34. Brown C., Morham S.G., Walsh D., Naghavi M.H. Focal adhesion proteins talin-1 and vinculin negatively affect paxillin phosphorylation and limit retroviral infection. J Mol Biol 2011, 410:761-777. 10.1016/j.jmb.2011.03.076.
35. Zhang L., Jia X., Zhang X., Sun J., Peng X., Qi T., et al. Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins. Proteome Sci 2010, 8:12. 10.1186/1477-5956-8-12.
36. Bando K., Ichlhara K., Toyoshlma H., Miyal K. Decreased activity of carnosinase in serum of patients with chronic liver disorders. Clin Chem 1986, 32:1563-1565.
37. Kong B., Michalski C.W., Hong X., Valkovskaya N., Rieder S., Abiatari I., et al. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling. Oncogene 2010, 29:5146-5158. 10.1038/onc.2010.258.
38. Yip P.Y., Kench J.G., Rasiah K.K., Benito R.P., Lee C.-S., Stricker P.D., et al. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011, 71:1638-1645. 10.1002/pros.21381.
39. Huang Y., Li L.-Z., Zhang C.Z.-Y., Yi C., Liu L.-L., Zhou X., et al. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 2012, 10:106. 10.1186/1479-5876-10-106.
40. Chang Q., Chen J., Beezhold K.J., Castranova V., Shi X., Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009, 8:64. 10.1186/1476-4598-8-64.
41. Kittl E.M., Hofmann J., Hartmann G., Sebesta C., Beer F., Bauer K., et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med 2000, 38:205-208. 10.1515/CCLM.2000.029.
42. Kanehisa M., Goto S., Sato Y., Furumichi M., Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012, 40:D109-D114. 10.1093/nar/gkr988.
43. Maglott D., Ostell J., Pruitt K.D., Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2005, 33:D54-D58. 10.1093/nar/gki031.
44. Hare B.J., Haseltine E., Fleming M., Chelsky D., McIntosh L., Allard R. A signature for immune response correlates with HCV treatment outcome in Caucasian subjects. J Proteomics 2014, [in press].